Khaled Moussawi, MD, PhD
The Translational Neuropsychiatry Through Neuromodulaton (TN²) laboratory investigates the neurobiology of substance use disorders and uses neuromodulation tools such as Low-Intensity Focused Ultrasound (LIFU), Transcranial Magnetic Stimulation (TMS), and Deep Brain Stimulation (DBS) to treat drug and alcohol addiction and related neuropsychiatric disorders. The goal of the lab is to identify neural biomarkers of craving and drug-seeking behaviors and leverage those findings to develop individualized clinical treatments with neuromodulation.
- Research Fellowship, 11/2020 - Substance use disorders, National Institute on Drug Abuse (NIH/NIDA)
- Clinical Fellowship, 6/2017 - Neuropsychiatry, Johns Hopkins Medicine
- Residency, 06/2016 - Neurology, Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School
- Internship, 06/2013 - Internal Medicine, Massachusetts General Hospital
- MD, PhD, 05/2012 - Medicine, Neuroscience, Medical University of South Carolina
Ventral Striatum
Cocaine-Related Disorders
Acetylcysteine
Receptors, Metabotropic Glutamate
Alpha7 Nicotinic Acetylcholine Receptor
Deep Brain Stimulation
Dopaminergic Neurons
Skull
G Protein-Coupled Inwardly-Rectifying Potassium Channels
Receptors, Dopamine D1
Cocaine
Fentanyl
Drug-Seeking Behavior
Receptors, Glycine
Mesencephalon
- UCSF Chen Scholar, Tianqiao and Chrissy Chen Institute, 2026
June 15, 2024 - May 31, 2026 - Modulating ventral striatal activity and connectivity with transcranial focused ultrasound as a putative novel intervention for cocaine use disorder , Co-Investigator . Sponsor: NIH, Sponsor Award ID: UG3DA060431
September 20, 2022 - August 31, 2024 - Limbic Pallidum DBS for the treatment of severe alcohol use disorder , Co-Investigator . Sponsor: NIH, Sponsor Award ID: UG3AA030505
February 1, 2021 - January 31, 2024 - TMS effects on circuit plasticity and drug seeking in mice. , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R00DA048085